NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial (NACAM)
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial
Sponsor: Beth Israel Deaconess Medical Center
Listed as NCT04750616, this PHASE2 trial focuses on Acute Kidney Injury and Ischemia Reperfusion Injury and remains actively recruiting participants. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jul 2022 — Aug 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Cedars-Sinai Medical Center
- Kaiser Permanente
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .